Meta-Analysis
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Nov 15, 2020; 11(11): 553-566
Published online Nov 15, 2020. doi: 10.4239/wjd.v11.i11.553
Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review
Li Zhang, Shuai Xue, Jie Hou, Guang Chen, Zhong-Gao Xu
Li Zhang, Jie Hou, Zhong-Gao Xu, Department of Nephrology, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Shuai Xue, Guang Chen, Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Zhang L and Chen G searched for articles and assessed search results; Zhang L evaluated the risk of bias in each included study; Zhang L and Xue S wrote the manuscript; Hou J checked the risk of bias in the assessment; Hou J was responsible for valuable intellectual content during the revision of the manuscript; any disagreement was resolved through discussions or consultations with Xu ZG; all authors issued a final approval for the submitted version.
Conflict-of-interest statement: The authors declare no conflict of interests.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Zhong-Gao Xu, MD, PhD, Director, Professor, Department of Nephrology, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. nephrology_jdyy@hotmail.com
Received: July 18, 2020
Peer-review started: July 18, 2020
First decision: August 9, 2020
Revised: August 22, 2020
Accepted: October 15, 2020
Article in press: October 15, 2020
Published online: November 15, 2020
Processing time: 117 Days and 20.8 Hours
Core Tip

Core Tip: Patients with type 2 diabetes are at increased risk for vascular complications, such as nephropathy, coronary artery disease, and retinopathy. Endothelin receptor (ER) antagonists might be a novel and beneficial drug for diabetic nephropathy (DN). However, no consistent conclusions regarding their effectiveness and safety for patients with DN have been presented. We conducted this meta-analysis of available clinical data on ER antagonists aimed to assess the effectiveness and safety of ER antagonists among patients with DN.